Compile Data Set for Download or QSAR
Report error Found 106 Enz. Inhib. hit(s) with all data for entry = 10161
TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279809(US10028960, Example 1-11 | 1-(((1R,3s,5S)-3-((4-((...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279809(US10028960, Example 1-11 | 1-(((1R,3s,5S)-3-((4-((...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279810(US10028960, Example 2 | 1-(((1R,3s,5S)-3-((4-((5-(...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279810(US10028960, Example 2 | 1-(((1R,3s,5S)-3-((4-((5-(...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279811(US10028960, Example 3 | (3-((6-methoxy-2-(methyl((...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279812(US10028960, Example 4 | (3-((6-methoxy-2-(((1R,3s,...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279815(US10028960, Example 7 | 5-(((1R,3s,5S)-3-((4-((5-(...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279815(US10028960, Example 7 | 5-(((1R,3s,5S)-3-((4-((5-(...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279823(US10028960, Example 1-6 | US10485803, Example 1-6 ...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279825(US10028960, Example 1-8 | US10485803, Example 1-8 ...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279830(US10028960, Example 1-13 | US10485803, Example 1-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279830(US10028960, Example 1-13 | US10485803, Example 1-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279831(US10028960, Example 1-14 | US10485803, Example 1-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279832(US10028960, Example 1-15 | US10485803, Example 1-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279834(US10028960, Example 1-17 | US10485803, Example 1-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279809(US10028960, Example 1-11 | 1-(((1R,3s,5S)-3-((4-((...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279810(US10028960, Example 2 | 1-(((1R,3s,5S)-3-((4-((5-(...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279810(US10028960, Example 2 | 1-(((1R,3s,5S)-3-((4-((5-(...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279811(US10028960, Example 3 | (3-((6-methoxy-2-(methyl((...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279811(US10028960, Example 3 | (3-((6-methoxy-2-(methyl((...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279812(US10028960, Example 4 | (3-((6-methoxy-2-(((1R,3s,...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279812(US10028960, Example 4 | (3-((6-methoxy-2-(((1R,3s,...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279813(US10028960, Example 5 | 3-((1R,3s,5S)-3-((4-((5-(h...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279813(US10028960, Example 5 | 3-((1R,3s,5S)-3-((4-((5-(h...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279814(US10028960, Example 6 | 5-(((1R,3s,5S)-3-((4-((5-(...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279815(US10028960, Example 7 | 5-(((1R,3s,5S)-3-((4-((5-(...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279815(US10028960, Example 7 | 5-(((1R,3s,5S)-3-((4-((5-(...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279816(US10028960, Example 8 | Isobutyl (1R,3s,5S)-3-((4-...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279816(US10028960, Example 8 | Isobutyl (1R,3s,5S)-3-((4-...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279816(US10028960, Example 8 | Isobutyl (1R,3s,5S)-3-((4-...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM420035(US10485803, Example 9 | US11110095, Example 9)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM420035(US10485803, Example 9 | US11110095, Example 9)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM420035(US10485803, Example 9 | US11110095, Example 9)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279819(US10028960, Example 1-2 | US10485803, Example 1-2 ...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279822(US10028960, Example 1-5 | US10485803, Example 1-5 ...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279824(US10028960, Example 1-7 | US10485803, Example 1-7 ...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279826(US10028960, Example 1-9 | US10485803, Example 1-9 ...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM420045(US10485803, Example 1-10 | US11110095, Example 1-1...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM420046(US10485803, Example 1-11 | US11110095, Example 1-1...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279829(US10028960, Example 1-12 | US10485803, Example 1-1...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279829(US10028960, Example 1-12 | US10485803, Example 1-1...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279829(US10028960, Example 1-12 | US10485803, Example 1-1...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279830(US10028960, Example 1-13 | US10485803, Example 1-1...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279830(US10028960, Example 1-13 | US10485803, Example 1-1...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279831(US10028960, Example 1-14 | US10485803, Example 1-1...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279831(US10028960, Example 1-14 | US10485803, Example 1-1...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279832(US10028960, Example 1-15 | US10485803, Example 1-1...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279832(US10028960, Example 1-15 | US10485803, Example 1-1...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279833(US10028960, Example 1-16 | US10485803, Example 1-1...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279833(US10028960, Example 1-16 | US10485803, Example 1-1...)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 106 total ) | Next | Last >>
Jump to: